SCHEMBL2391692

SCHEMBL2391692

CCCCc1c(C(=O)O)cnn1-c1ncc(Cl)c(NC2CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 10/20 0.41
NR2F2 P24468 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
JAK1 P23458 2/20 0.38
HDAC3 O15379 1/20 0.38
JAK2 O60674 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391311 0.83 GPR142 (0.63) GPR142TYRO3MERTKFLT3GAS6
SCHEMBL2391674 0.80 GPR142 (0.47) GPR142TYRO3MERTKFLT3GAS6
SCHEMBL2393491 0.77 GPR142 (0.42) GPR142TYRO3MERTKFLT3GAS6
SCHEMBL2397438 0.73 GPR142 (0.64) GPR142
SCHEMBL2393120 0.71 GPR142 (0.79) GPR142NR2F2NPSR1KDM4EMAPT
SCHEMBL2397101 0.67 GPR142 (0.59) GPR142
SCHEMBL2393961 0.66 GPR142 (0.75) GPR142
SCHEMBL2079637 0.63 NR4A3 (0.59) NPSR1MAPTMAPK1MEN1ALDH1A1
SCHEMBL14981603 0.62 KMT2A (0.42) JAK1TYK2JAK3KMT2ATYRO3
SCHEMBL31612124 0.62 KMT2A (0.50) KMT2ATYRO3MERTKFLT3GAS6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079728-B1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES AMGEN INC (US) 2013-09-25 EP disclosed
US-8022061-B2 5-(Methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide; for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions AMGEN INC. (US) 2011-09-20 US disclosed
EP-2079728-A1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES Amgen Inc. (US) 2009-07-22 EP disclosed
EP-2079711-A2 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-07-22 EP disclosed
US-20080153778-A1 N-aryl pyrazole compounds, compositions, and methods for their use AMGEN INC. 2008-06-26 US disclosed
WO-2008050301-A2 2- PHENYL- 6-AMINOCARBONYL- PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-05-02 WO disclosed
WO-2008045484-A1 N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES AMGEN INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153778-A1 N-aryl pyrazole compounds, compositions, and methods for their use GLP1R, GPR119, NAT1 GPR142 3378/4885NR2F2 988/4885NPSR1 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.